ABT-199 (Venetoclax), solely targeting BCL2 within the sub-nanomolar-range, shows clinical efficacy in CLL [24], is heavily explored in clinical trials and shows promising results in ER+ BC patient-derived xenotransplants (PDX) [25]. This evidence concerns the gene BCL2 and breast cancer.